{"Title": "Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers", "Year": 2016, "Source": "Eur. J. Clin. Pharmacol.", "Volume": "72", "Issue": 2, "Art.No": null, "PageStart": 195, "PageEnd": 201, "CitedBy": 9, "DOI": "10.1007/s00228-015-1970-4", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84954289810&origin=inward", "Abstract": "\u00a9 2015 Springer-Verlag Berlin Heidelberg.Purpose: Oxcarbazepine (OXC), a second-generation antiepileptic, and its chiral metabolite 10-hydroxycarbazepine (MHD) are substrates of P-glycoprotein, which can be inhibited by verapamil. This study evaluated the influence of verapamil on the pharmacokinetics of OXC and MHD enantiomers in healthy volunteers. Methods: Healthy volunteers (n = 12) on occasion O (OXC monotherapy) received 300 mg OXC/12 h for 5 days, and on the O + V occasion (treatment with OXC + verapamil), they received 300 mg OXC/12 h and 80 mg verapamil/8 h for 5 days. Blood samples were collected over a period of 12 h. Total and free plasma concentrations of OXC and the MHD enantiomers were evaluated by LC-MS/MS. Noncompartmental pharmacokinetic analysis was performed using the WinNonlin program. Results: The kinetic disposition of MHD was enantioselective with plasma accumulation (AUC0-12 S-(+)/R-(-) ratio of 4.38) and lower fraction unbound (0.37 vs 0.42) of the S-(+)-MHD enantiomer. Treatment with verapamil reduced the OXC mean residence time (4.91 vs 4.20 h) and apparent volume of distribution (4.72 vs 3.15 L/kg). Verapamil also increased for both MHD enantiomers C max total [R-(-)-MHD: 2.65 vs 2.98 \u03bcg/mL and S-(+)-MHD: 10.15 vs 11.60 \u03bcg/mL], C average [R-(-)-MHD: 1.98 vs 2.18 \u03bcg/mL and S-(+)-MHD: 8.10 vs 8.83 \u03bcg/mL], and AUC0-12 [R-(-)-MHD: 23.79 vs 26.19 \u03bcg h/mL and S-(+)-MHD: 97.87 vs 108.35 \u03bcg h/mL]. Conclusion: Verapamil increased the AUC values of both MDH enantiomers, which is probably related to the inhibition of intestinal P-glycoprotein. Considering that the exposure of both MHD enantiomers was increased in only 10 %, no OXC dose adjustment could be recommended in the situation of verapamil coadministration.", "AuthorKeywords": ["10-hydroxycarbazepine", "Enantiomers", "Oxcarbazepine", "P-glycoprotein", "Pharmacokinetics"], "IndexKeywords": ["Adult", "Anticonvulsants", "Carbamazepine", "Cross-Over Studies", "Female", "Healthy Volunteers", "Humans", "Male", "P-Glycoprotein", "Stereoisomerism", "Verapamil", "Young Adult"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 0, "EID": "2-s2.0-84954289810", "SubjectAreas": [["Pharmacology", "PHAR", "3004"], ["Pharmacology (medical)", "MEDI", "2736"]], "AuthorData": {"37107526200": {"Name": "De Jesus Antunes N.", "AuthorID": "37107526200", "AffiliationID": "60008088", "AffiliationName": "Departamento de An\u00e1lises Cl\u00ednicas, Toxicol\u00f3gicas e Bromatol\u00f3gicas, Faculdade de Ci\u00eancias Farmac\u00eauticas de Ribeir\u00e3o Preto, Universidade de S\u00e3o Paulo"}, "6504308514": {"Name": "Tozatto E.", "AuthorID": "6504308514", "AffiliationID": "60008088", "AffiliationName": "Departamento de An\u00e1lises Cl\u00ednicas, Toxicol\u00f3gicas e Bromatol\u00f3gicas, Faculdade de Ci\u00eancias Farmac\u00eauticas de Ribeir\u00e3o Preto, Universidade de S\u00e3o Paulo"}, "7201744111": {"Name": "Marques M.", "AuthorID": "7201744111", "AffiliationID": "60008088", "AffiliationName": "Departamento de An\u00e1lises Cl\u00ednicas, Toxicol\u00f3gicas e Bromatol\u00f3gicas, Faculdade de Ci\u00eancias Farmac\u00eauticas de Ribeir\u00e3o Preto, Universidade de S\u00e3o Paulo"}, "7004245288": {"Name": "Lanchote V.", "AuthorID": "7004245288", "AffiliationID": "60008088", "AffiliationName": "Departamento de An\u00e1lises Cl\u00ednicas, Toxicol\u00f3gicas e Bromatol\u00f3gicas, Faculdade de Ci\u00eancias Farmac\u00eauticas de Ribeir\u00e3o Preto, Universidade de S\u00e3o Paulo"}, "6603138505": {"Name": "Wichert-Ana L.", "AuthorID": "6603138505", "AffiliationID": "60008088", "AffiliationName": "Departamento de Cl\u00ednica M\u00e9dica, Faculdade de Medicina de Ribeir\u00e3o Preto, Universidade de S\u00e3o Paulo"}, "7006029024": {"Name": "Coelho E.", "AuthorID": "7006029024", "AffiliationID": "60008088", "AffiliationName": "Departamento de Cl\u00ednica M\u00e9dica, Faculdade de Medicina de Ribeir\u00e3o Preto, Universidade de S\u00e3o Paulo"}, "8536932300": {"Name": "Della Pasqua O.", "AuthorID": "8536932300", "AffiliationID": "60019816", "AffiliationName": "Division of Pharmacology, School of Science, University of Leiden"}, "56781465300": {"Name": "Alexandre Junior V.", "AuthorID": "56781465300", "AffiliationID": "60008088", "AffiliationName": "Departamento de Neuroci\u00eancias e Ci\u00eancias Do Comportamento, Faculdade de Medicina de Ribeir\u00e3o Preto, Universidade de S\u00e3o Paulo"}, "7003682901": {"Name": "Takayanagui O.", "AuthorID": "7003682901", "AffiliationID": "60008088", "AffiliationName": "Departamento de Neurologia, Psiquiatria e Psicologia M\u00e9dica, Faculdade de Medicina de Ribeir\u00e3o Preto, Universidade de S\u00e3o Paulo"}}}